Raymond James Maintains Strong Buy on ADMA Biologics, Raises Price Target to $6
Portfolio Pulse from richadhand@benzinga.com
Raymond James analyst Elliot Wilbur maintains a Strong Buy rating on ADMA Biologics (NASDAQ:ADMA) and raises the price target from $5 to $6.
August 10, 2023 | 1:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Raymond James maintains a Strong Buy rating on ADMA Biologics and raises the price target from $5 to $6.
The news of Raymond James maintaining a Strong Buy rating on ADMA Biologics and raising the price target is directly related to the company and is likely to have a positive impact on the stock price in the short term. Investors may see this as a sign of confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100